Global Radionuclide Injection Market – Industry Trends and Forecast to 2029

Radionuclide Injection Market Analysis and Size

According to World Health Organization, 14.1 million cases registered in 2012 of cancer globally. WHO also stated that more than 33% cancer cases are associated with smoking and chewing tobacco. Radionuclide injection is a radioactive chemical used for diagnostic purpose using positron emission tomography (PET). This injection are generally used for diagnosis of cancer and coronary artery disease. Radionuclide injection contains fluoro-D-glucose as its active ingredient and is given intravenously. As soon as it is injected into the body, it raises the level of glucose under pathophysiological circumstances.

Data Bridge Market Research analyses that the radionuclide injection market is expected to undergo a CAGR of 10.00% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Radionuclide Injection Market Scope and Segmentation       

Market Definition

Radionuclide injection is radioactive substance used for diagnostic purpose with positron emission tomography (PET). Advancement in radiopharmaceutical technologies along with improved hardware and software of PET imaging are the primary factors driving the growth of radionuclide injection market.

Radionuclide Injection Market Dynamics

Drivers

• Developments in radiopharmaceutical technologies

Radionuclide injection market growth is primarily driven by developments in radiopharmaceutical technologies and better PET imaging hardware and software. Additionally, the radionuclide injection market will grow rapidly due to improved diagnostic accuracy and the low risk associated with this injection.

• Upsurge in cancer cases

The radionuclide injection market will expand greatly due to rising cancer and cardiovascular disease rates. The market for radionuclide injection will increase significantly if major industry players engage with local and regional players.

Opportunities

Radionuclides may be used in therapy, and this has been known for many years. Many benign and malignant illnesses have been effectively treated using a variety of radionuclides, including iodine-131, phosphorous-32, strontium-90, and yttrium-90. The recent development of several new radionuclides and radiopharmaceuticals for the treatment of neuroendocrine and other malignant or non-malignant tumours has accelerated the development of this area of nuclear medicine. The discipline of radionuclide therapy is currently in an exciting phase and is set to experience more expansion and advancement in the years to come.

Restraints/Challenges

Radionuclide injection is expensive, which will limit market expansion. The growth of this market would also be hampered by the scarcity of skilled professionals in developing nations.

This radionuclide injection market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the radionuclide injection market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Radionuclide Injection Market

People have been compelled to embrace difficult norms of social isolation and economic isolation as a result of the global COVID-19 health and economic devastation. To ensure their and their patients' safety, medical staff has been instructed to alter their daily schedules. The use of radionuclide treatment in therapeutic settings has grown. Oncology is where the majority of therapeutic radionuclide techniques are used. Due to co-morbidities and immunosuppression, cancer patients are a particularly weak and at-risk population. Another danger that needs to be taken into account while planning treatments is COVID-19. For these patients, therapeutic, preventative, and supportive measures might need to change. The most common radionuclide therapies involve patients with differentiated thyroid cancer (DTC) who need radioiodine therapy (RAI), patients with neuroendocrine tumours (NETs) who need peptide receptor radionuclide therapy (PRRT), patients with hepatocellular carcinoma (HCC) who need therapy with radiolabelled microspheres, and patients with prostate cancer and bone metastasis who need radionuclide palliative therapy.

Global Radionuclide Injection Market Scope

The radionuclide injection market is segmented on the basis of type, application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

????

• ??n??r
• ??r?n?r? ?rt?r? D??????
• ?th?r?

???l???t??n

• ?????t?l?
• ?l?n???
• D??gn??t??? ??nt?r

Radionuclide Injection Market Regional Analysis/Insights

The radionuclide injection market is analysed and market size insights and trends are provided by country, type, application as referenced above.

The countries covered in the radionuclide injection market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Due to high healthcare infrastructure, North America is expected to dominate the global radionuclide injection market.

Asia-Pacific is expected to grow the market owing to increasing geriatric population and cancer incidences.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Radionuclide Injection Market Share Analysis

The radionuclide injection market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to radionuclide injection market.

Some of the major players operating in the radionuclide injection market are:

• Sofie Co. (U.S.)
• The Qu??n'? Health System Corporation (U.S.)
• ?r??d ???t???? Inc. (U.S.)
• N?? U?? LLC (U.S.)
• ????tr?n ?R? (U.S.)
• Siemens Healthcare GmbH (Germany)
• ?h?rt??h L?b?r?t?r??? (U.S.)
• ?r??????n Nu?l??r LLC (U.S.)

SKU-68816